Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: A cumulative meta-analysis

Autoimmunity Reviews - Tập 13 Số 8 - Trang 788-794 - 2014
Víctor Manuel Martínez-Taboada1, Marcos López‐Hoyos2, Javier Narváez3, Pedro Muñoz4
1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla-IFIMAV, Spain
2Division of Immunology, Hospital Universitario Marqués de Valdecilla-IFIMAV, Spain.
3Division of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain.
4Gerencia Atención Primaria, Servicio Cántabro de Salud, Facultad de Medicina, Universidad de Cantabria, Santander, Spain.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Martínez-Taboada, 2000, Arteritis de células gigantes, Seminarios de Reumatología, 1, 141

Aiello, 1993, Visual prognosis in giant cell arteritis, Ophthalmology, 100, 550, 10.1016/S0161-6420(93)31608-8

Hayreh, 2003, Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy, Ophthalmology, 110, 1204, 10.1016/S0161-6420(03)00228-8

Liozon, 2001, Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients, Am J Med, 111, 211, 10.1016/S0002-9343(01)00770-7

Cid, 1998, Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis, Arthritis Rheum, 41, 26, 10.1002/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0

González-Gay, 1998, Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment, Arthritis Rheum, 41, 1497, 10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z

Salvarani, 2009, Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis, Rheumatology (Oxford), 48, 250, 10.1093/rheumatology/ken465

Berger, 2009, High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition, Rheumatology (Oxford), 48, 258, 10.1093/rheumatology/ken480

Nesher, 2004, Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis, Arthritis Rheum, 50, 1332, 10.1002/art.20171

Lee, 2006, Antiplatelet and anticoagulant therapy in patients with giant cell arteritis, Arthritis Rheum, 54, 3306, 10.1002/art.22141

Hellmann, 2004, Low-dose aspirin in the treatment of giant cell arteritis, Arthritis Rheum, 50, 1026, 10.1002/art.20172

Mukhtyar, 2009, EULAR recommendations for the management of large vessel vasculitis, Ann Rheum Dis, 68, 318, 10.1136/ard.2008.088351

Gonzalez-Gay, 2004, Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis, Medicine (Baltimore), 83, 342, 10.1097/01.md.0000145369.25558.b5

Narváez, 2008, Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis, Clin Exp Rheumatol, 26, S57

Stroup, 2000, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group, JAMA, 283, 2008, 10.1001/jama.283.15.2008

Moher, 2009, The PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, e1000097, 10.1371/journal.pmed.1000097

Wells

Vandenbroucke, 2007, Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration, Ann Intern Med, 147, W163, 10.7326/0003-4819-147-8-200710160-00010-w1

2011, GRADE handbook for grading quality of evidence and strength of recommendation. version 3.6

Guyatt, 2008, Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD

Higgins, 2003, Measuring inconsistency in meta-analysis, BMJ, 327, 557, 10.1136/bmj.327.7414.557

DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2

Sterne, 2011, Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials, BMJ, 343, d4002, 10.1136/bmj.d4002

Borenstein, 2009, Publication bias, 277

Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629

Lau, 1995, Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care, J Clin Epidemiol, 48, 45, 10.1016/0895-4356(94)00106-Z

Borenstein, 2005

Armona, 1995, Giant cell arteritis. A study of 191 patients, Med Clin (Barc), 105, 734

Brack, 1999, Disease pattern in cranial and large-vessel giant cell arteritis, Arthritis Rheum, 42, 311, 10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F

Huston, 1978, Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study, Ann Intern Med, 88, 162, 10.7326/0003-4819-88-2-162

Duhaut, 1999, Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Artérite à Cellules Géantes, Ann Rheum Dis, 58, 335, 10.1136/ard.58.6.335

Myklebust, 1996, A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis, Br J Rheumatol, 35, 1161, 10.1093/rheumatology/35.11.1161

Franzén, 1992, Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984–1988, J Rheumatol, 19, 273

Weisman, 2002, Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events, Arch Intern Med, 162, 2197, 10.1001/archinte.162.19.2197

Caspi, 2000, The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients, Arthritis Rheum, 43, 103, 10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C

Segal, 2003, Early and late effects of low-dose aspirin on renal function in elderly patients, Am J Med, 115, 462, 10.1016/S0002-9343(03)00436-4

Lau, 1992, Cumulative meta-analysis of therapeutic trials for myocardial infarction, N Engl J Med, 327, 248, 10.1056/NEJM199207233270406

Martinez-Taboada, 2003, Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy, Rheumatology (Oxford), 42, 1055, 10.1093/rheumatology/keg293

Machado, 1989, A population-based case–control study of temporal arteritis: evidence for an association between temporal arteritis and degenerative vascular disease?, Int J Epidemiol, 18, 836, 10.1093/ije/18.4.836

Duhaut, 1998, Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case–control study. Groupe de Recherche sur l'Artérite à Cellules Géantes, Arthritis Rheum, 41, 1960, 10.1002/1529-0131(199811)41:11<1960::AID-ART10>3.0.CO;2-X

Uddhammar, 2002, Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden, J Rheumatol, 29, 737

Spiera, 2006, Therapy for giant cell arteritis: can we do better?, Arthritis Rheum, 54, 3071, 10.1002/art.22142

de Souza, 2010, Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis, Circ J, 74, 1236, 10.1253/circj.CJ-09-0905

Danesh-Meyer, 2001, The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy, Ophthalmology, 108, 593, 10.1016/S0161-6420(00)00602-3